Emergence of ASEAN Clinical Trial Market & the Importance of Southeast Asia

author

By: Kamaljeet --

03 August, 2012

Emergence of ASEAN Clinical Trial Market & the Importance of Southeast Asia
WHITEPAPER

In todayï¾Ãƒâ€šÃ‚Æ’??s clinical research world CROs provide substantial global capacity for drug developers and have become a critical contributor to clinical trial activities. Beside Cost & Quality, Timeliness has become a critical factor for efficiency & effectiveness in the drug development process; clinical trials conducted by CROs are completed in about 30%-40% more quickly than those conducted in-house by Pharma companies. The number of clinical studies conducted in Asia, Central and Eastern Europe and Latin America is constantly rising. Asian countries which consist 60% of the global population are the most preferred future outsourcing destinations for conducting clinical trials. Access to emerging region like Southeast Asia can be challenging for Sponsors/Pharma companies. Being aware about the opportunities & need to recruit patients, these companies may be na??ve to operations in this region by relying on some chosen CROs to provide clinical trial guidance & site selection.